Lineage Cell Therapeutics Inc. — Proxy Solicitation & Information Statement 2022

May 1, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Schedule 14A Information

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Check the appropriate box:

• ☐ Preliminary Proxy Statement
• ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
• ☐ Definitive Proxy Statement
• ☒ Definitive Additional Materials
• ☐ Soliciting Material Pursuant to §240.14a-12

Lineage Cell Therapeutics, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

• ☒ No fee required.
• ☐ Fee paid previously with preliminary materials.
• ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

P.O. BOX 8016, CARY, NC 27512-9903

Lineage Cell Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials

for the Shareholders Meeting to be held on June 16, 2022

For shareholders of record as of April 20, 2022 This communication presents only an overview of the proposals to

be voted upon at the meeting. The complete proxy materials are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy materials, and to obtain directions to attend the
meeting, go to: www.proxydocs.com/LCTX

To vote your proxy while visiting this site, you will need the 12 diait control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be
distributed by making them available on the internet.

Have the 12 digit control number located in the shaded box above available when you access the website and follow the instructions.

The Notice and Proxy Statement and Annual Report are available at www.proxydocs.com/LCTX. If you want to receive a paper or e-mail copy of these proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 06, 2022.

SEE REVERSE FOR FULL AGENDA

Lineage Cell Therapeutics, Inc.

2022 Annual Meeting of Shareholders

the board of directors recommends a vote:

FOR EACH NOMINEE LISTED IN PROPOSAL 1 AND FOR ON PROPOSALS 2 AND 3

proposal

1.

To elect nine directors to hold office until the 2023 anual meeting of shareholders and until their respective successors are duly elected and

qualified. 1.01 Alfred D. Kingsley 1.02 Dipti Amin 1.03 Deborah Andrews 1.04 Don M. Bailey

• 1.05 Neal C. Bradsher
• 1.06 Brian M. Culley
• 1.07 Anula Jayasuriya
• 1.08 Michael H. Mulroy

• 1.09 Angus C. Russell

• To ratify the appointment of WithumSmith+Brown, PC as the company's independent registered public accounting firm for its fiscal year ending

To approve, on an advisory basis, the compensation paid to the company's named executive officers. 3.

NOTE: To transact such other business as may properly come before the meeting or any adjournment thereof.